PainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial Comparison

PainReform (NASDAQ:PRFX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

37.3% of PainReform shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

PainReform has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for PainReform and Citius Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Citius Pharmaceuticals	1	2	1	0	2.00

Citius Pharmaceuticals has a consensus target price of $6.00, suggesting a potential upside of 575.90%. Given Citius Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than PainReform.

Earnings and Valuation

This table compares PainReform and Citius Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	N/A	N/A	-$14.59 million	($147.33)	-0.01
Citius Pharmaceuticals	N/A	N/A	-$37.43 million	($3.37)	-0.26

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PainReform and Citius Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-55.93%	-31.00%

Summary

PainReform beats Citius Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.